| 引用本文:乔静敏1，张沉冰2，张立双1，赵志刚1，魏曼1.津力达结合门冬胰岛素50治疗2型糖尿病的临床价值分析[J].世界中医药,2016,(10):. |
|
| 津力达结合门冬胰岛素50治疗2型糖尿病的临床价值分析 |
| Clinical Value Analysis of Jinlida Combined with Insulin Aspart 50 on Type 2 Diabetes |
| 投稿时间：2016-07-19 |
| DOI：10.3969/j.issn.1673-7202.2016.10.029 |
| 中文关键词: 津力达 门冬胰岛素50 2型糖尿病 胰岛β细胞功能 |
| English Keywords:Jinlida Insulin aspart 50 Type 2 diabetes Pancreatic β cell |
| 基金项目:河北省科技厅支持项目(编号:152777128) |
|
| 摘要点击次数: 819 |
| 全文下载次数: 713 |
| 中文摘要: |
| 目的:研究分析津力达结合门冬胰岛素50治疗2型糖尿病的临床价值。方法:选取2012年10月至2015年5月石家庄市第一医院收治确诊的94例2型糖尿病患者,对纳入研究的全体患者采取随机数字表法将其均分为观察组与对照组,每组各含病例47例。对照组给予适当的门冬胰岛素50皮下注射给药,观察组则在前者前提下实施津力达治疗,观察比较2组患者治疗后血糖、总有效情况等。结果:干预后,2组FPG,2 hPG,HbA1c,HOMA-IR、HOMA-β分别与本组内干预前比较差异有统计学意义(P<0.01);观察组干预后FPG,2 hPG,HbA1c,HOMA-IR、HOMA-β分别与对照组干预后比较差异有统计学意义(P<0.01);观察组干预后总有效情况显著较对照组差异有统计学意义(P<0.05)。结论:津力达结合门冬胰岛素50能显著降低2型糖尿病患者血糖情况,并改善其胰岛功能,临床价值显著。 |
| English Summary: |
| To analyze the clinical value of Jinlida combined with insulin therapy on type 2 diabetes. Methods:Totally 94 cases of patients with type 2 diabetes in the hospital from October 2012 to May 2015 were divided into 2 groups randomly, observation group and control group, each 47 cases. The observation group was given insulin aspart 50 injection, and the control group Jinlida. After treatment, two groups of patients′ blood glucose and total efficacy were compared. Results:After intervention, 2 hPG, FPG, HbA1c, HOMA IR, and HOMA-beta of the 2 groups were significantly different from those before treatment (P<0.01); The observation group′s 2 hPG， FPG, HbA1c, HOMA IR, and HOMA-beta were very largely different than those of the control group with statistical significance (P<0.01); The observation group′s total effecacy was significantly better than that of the control group (P<0.05). Conclusion:The combination of Jinlida and insulin aspart 50 significantly reduced the blood sugar in type 2 diabetes patients and improved the patient′s corresponding islet function with outstanding clinical value. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
